Oppenheimer Asset Management Inc. Increases Position in Genmab A/S Sponsored ADR (NASDAQ:GMAB)

Oppenheimer Asset Management Inc. lifted its stake in shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB - Free Report) by 20.5% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 249,468 shares of the company's stock after purchasing an additional 42,361 shares during the period. Oppenheimer Asset Management Inc.'s holdings in Genmab A/S were worth $4,885,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in GMAB. Deep Track Capital LP acquired a new position in shares of Genmab A/S during the 4th quarter worth approximately $41,740,000. Brandywine Global Investment Management LLC purchased a new stake in shares of Genmab A/S during the 4th quarter valued at approximately $33,804,000. Two Sigma Advisers LP raised its position in shares of Genmab A/S by 168.8% during the 4th quarter. Two Sigma Advisers LP now owns 1,653,500 shares of the company's stock valued at $34,509,000 after buying an additional 1,038,400 shares during the period. Two Sigma Investments LP raised its position in shares of Genmab A/S by 122.2% during the 4th quarter. Two Sigma Investments LP now owns 1,706,364 shares of the company's stock valued at $35,612,000 after buying an additional 938,455 shares during the period. Finally, Marshall Wace LLP raised its position in shares of Genmab A/S by 162.2% during the 4th quarter. Marshall Wace LLP now owns 1,122,296 shares of the company's stock valued at $23,422,000 after buying an additional 694,243 shares during the period. 7.07% of the stock is currently owned by institutional investors and hedge funds.

Genmab A/S Stock Performance

Shares of NASDAQ:GMAB traded down $0.23 during trading on Friday, hitting $20.50. The company's stock had a trading volume of 727,649 shares, compared to its average volume of 1,222,343. The business has a 50 day moving average price of $20.98 and a two-hundred day moving average price of $20.70. The company has a market capitalization of $13.15 billion, a PE ratio of 11.65, a P/E/G ratio of 6.76 and a beta of 0.96. Genmab A/S Sponsored ADR has a fifty-two week low of $17.24 and a fifty-two week high of $28.56.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported $0.31 EPS for the quarter, topping the consensus estimate of $0.23 by $0.08. The business had revenue of $715.00 million during the quarter, compared to the consensus estimate of $5.17 billion. Genmab A/S had a net margin of 35.11% and a return on equity of 18.08%. As a group, equities analysts expect that Genmab A/S Sponsored ADR will post 1.45 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

GMAB has been the topic of several analyst reports. Wall Street Zen lowered shares of Genmab A/S from a "buy" rating to a "hold" rating in a research report on Saturday, June 14th. Truist Financial reduced their price target on shares of Genmab A/S from $50.00 to $45.00 and set a "buy" rating on the stock in a research report on Tuesday, March 11th. Sanford C. Bernstein lowered shares of Genmab A/S from a "market perform" rating to an "underperform" rating in a research report on Tuesday, April 1st. William Blair raised shares of Genmab A/S from a "market perform" rating to an "outperform" rating in a research report on Tuesday, March 11th. Finally, HC Wainwright reissued a "buy" rating and issued a $37.00 target price (down previously from $50.00) on shares of Genmab A/S in a research report on Wednesday, April 9th. One research analyst has rated the stock with a sell rating, four have given a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, Genmab A/S has a consensus rating of "Moderate Buy" and a consensus price target of $37.60.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.